Eleanor Tomczyk, MD
Plastic and Reconstructive Surgery · Boston, MANPI 1902243579
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (54.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. AbbVie accounts for 74.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2023 at $3,851 and has fallen 72.8% since, to $1,045 in 2025.
Across 121 payments — averaging $47.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- BD$1K
- Integra Lifesciences Corporation$221
- Solventum Corporation$87
- Axogen$47
- Convatec Inc.$28
What the payments were for
- Speaking & faculty fees$1,10019%
- Travel & lodging$1,54927%
- Food & beverage$3,14154%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 111 | $4,307 |
| BD | 1 | $1,100 |
| Integra Lifesciences Corporation | 4 | $221 |
| Solventum Corporation | 3 | $87 |
| Axogen | 1 | $47 |
| Convatec Inc. | 1 | $28 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,790 in reported general payments places this provider in the 75th percentile of 67 plastic and reconstructive surgery providers in Massachusetts.
See all plastic and reconstructive surgery providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other plastic and reconstructive surgery in Boston
- Kyle EberlinBoston$445K
- Dennis OrgillBoston$87K
- Jonathan FriedstatBoston$59K
- Ashley BoustanyBoston$46K
- Devin O'Brien-CoonBoston$34K
- Jonathan BekiszBoston$23K
- Krystle TuanoBoston$20K
- Christopher HomsyBoston$12K
- Arthur CelestinBoston$6K
- Frank LauBoston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.